Metrics to compare | 388870 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship388870PeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.0x | −3.6x | −0.4x | |
PEG Ratio | −1.09 | −0.02 | 0.00 | |
Price/Book | 5.9x | 1.6x | 2.6x | |
Price / LTM Sales | - | 7.4x | 3.0x | |
Upside (Analyst Target) | - | 0.0% | 56.2% | |
Fair Value Upside | Unlock | 19.1% | 8.9% | Unlock |
Pharos iBio Co., Ltd. engages in the development of treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of recurrent ovarian cancer; PHI-501 for refractory solid cancer; PHI-301 for the treatment of refractory lung cancer; and PHI-601 for the treatment of menin inhibitor. The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.